• Something wrong with this record ?

Liposomal delivery systems for anti-cancer analogues of vitamin E

S. Koudelka, P. Turanek Knotigova, J. Masek, L. Prochazka, R. Lukac, AD. Miller, J. Neuzil, J. Turanek,

. 2015 ; 207 (-) : 59-69. [pub] 20150407

Language English Country Netherlands

Document type Journal Article, Research Support, Non-U.S. Gov't, Review

Persistent link   https://www.medvik.cz/link/bmc16010351

Pro-apoptotic analogues of vitamin E (VE) exert selective anti-cancer effect on various animal cancer models. Neither suitable formulation of α-tocopheryl succinate (α-TOS), representative semi-synthetic VE analogue ester, nor suitable formulations of the other VE analogues for clinical application have been reported yet. The major factor limiting the use of VE analogues is their low solubility in aqueous solvents. Due to the hydrophobic character of VE analogues, liposomes are predetermined as suitable delivery system. Liposomal formulation prevents undesirable side effects of the drug, enhances the drug biocompatibility, and improves the drug therapeutic index. Liposomal formulations of VE analogues especially of α-TOS and α-tocopheryl ether linked acetic acid (α-TEA) have been developed. The anti-cancer effect of these liposomal VE analogues has been successfully demonstrated in pre-clinical models in vivo. Present achievements in: (i) preparation of liposomal formulations of VE analogues, (ii) physico-chemical characterization of these developed systems and (iii) testing of their biological activity such as induction of apoptosis and evaluation of anti-cancer effect are discussed in this review.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16010351
003      
CZ-PrNML
005      
20160414122005.0
007      
ta
008      
160408s2015 ne f 000 0|engg|
009      
AR
024    7_
$a 10.1016/j.jconrel.2015.04.003 $2 doi
024    7_
$a 10.1016/j.jconrel.2015.04.003 $2 doi
035    __
$a (PubMed)25861728
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Koudelka, Stepan $u Department of Pharmacology and Immunotherapy, Veterinary Research Institute, Brno, Czech Republic; International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic. Electronic address: koudelka@vri.cz.
245    10
$a Liposomal delivery systems for anti-cancer analogues of vitamin E / $c S. Koudelka, P. Turanek Knotigova, J. Masek, L. Prochazka, R. Lukac, AD. Miller, J. Neuzil, J. Turanek,
520    9_
$a Pro-apoptotic analogues of vitamin E (VE) exert selective anti-cancer effect on various animal cancer models. Neither suitable formulation of α-tocopheryl succinate (α-TOS), representative semi-synthetic VE analogue ester, nor suitable formulations of the other VE analogues for clinical application have been reported yet. The major factor limiting the use of VE analogues is their low solubility in aqueous solvents. Due to the hydrophobic character of VE analogues, liposomes are predetermined as suitable delivery system. Liposomal formulation prevents undesirable side effects of the drug, enhances the drug biocompatibility, and improves the drug therapeutic index. Liposomal formulations of VE analogues especially of α-TOS and α-tocopheryl ether linked acetic acid (α-TEA) have been developed. The anti-cancer effect of these liposomal VE analogues has been successfully demonstrated in pre-clinical models in vivo. Present achievements in: (i) preparation of liposomal formulations of VE analogues, (ii) physico-chemical characterization of these developed systems and (iii) testing of their biological activity such as induction of apoptosis and evaluation of anti-cancer effect are discussed in this review.
650    _2
$a zvířata $7 D000818
650    _2
$a protinádorové látky $x aplikace a dávkování $x chemie $7 D000970
650    _2
$a apoptóza $x účinky léků $7 D017209
650    _2
$a farmaceutická chemie $7 D002626
650    _2
$a lékové transportní systémy $x metody $7 D016503
650    _2
$a lidé $7 D006801
650    _2
$a lipidy $x chemie $7 D008055
650    _2
$a liposomy $7 D008081
650    _2
$a nádory $x farmakoterapie $x patologie $7 D009369
650    _2
$a rozpustnost $7 D012995
650    _2
$a vitamin E $x aplikace a dávkování $x analogy a deriváty $x chemie $7 D014810
650    _2
$a alfa-tokoferol $x aplikace a dávkování $7 D024502
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Turanek Knotigova, Pavlina $u Department of Pharmacology and Immunotherapy, Veterinary Research Institute, Brno, Czech Republic.
700    1_
$a Masek, Josef $u Department of Pharmacology and Immunotherapy, Veterinary Research Institute, Brno, Czech Republic.
700    1_
$a Prochazka, Lubomir $u Department of Pharmacology and Immunotherapy, Veterinary Research Institute, Brno, Czech Republic.
700    1_
$a Lukac, Robert $u Department of Pharmacology and Immunotherapy, Veterinary Research Institute, Brno, Czech Republic.
700    1_
$a Miller, Andrew D $u Institute of Pharmaceutical Science, King's College London, London, United Kingdom.
700    1_
$a Neuzil, Jiri $u School of Medical Science, Griffith University, Southport, Qld, Australia; Institute of Biotechnology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Turanek, Jaroslav $u Department of Pharmacology and Immunotherapy, Veterinary Research Institute, Brno, Czech Republic. Electronic address: turanek@vri.cz.
773    0_
$w MED00002621 $t Journal of controlled release official journal of the Controlled Release Society $x 1873-4995 $g Roč. 207, č. - (2015), s. 59-69
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25861728 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20160414122049 $b ABA008
999    __
$a ok $b bmc $g 1113780 $s 934719
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 207 $c - $d 59-69 $e 20150407 $i 1873-4995 $m Journal of controlled release $n J Controlled Release $x MED00002621
LZP    __
$a Pubmed-20160408

Find record

Citation metrics

Archiving options